US › Healthcare

OnKure Therapeutics, Inc. (OKUR)

US · Healthcare · Biotechnology

$2.10-1.41%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-15.3M

EPS

$-0.31

EPS estimate

$-0.58

EPS came in at -0.31 against a street estimate of -0.58 — a beat of 46.6%.

Key statistics

Market cap

$95.0M

Forward P/E

0.0

P/B

0.69

Book value

$4.25

EPS (TTM)

$-3.14

52-week high

$5.38

52-week low

$2.13

50-day MA

$3.37

200-day MA

$3.65

Beta

0.75

Analyst view

Analysts rate OnKure Therapeutics, Inc. a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $15.50.

Shareholding

Insiders

10.17%

Institutions

93.42%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	9.87%
Bvf Inc	7.99%
StepStone Group LLC	6.57%
ADAR1 Capital Management LLC	5.53%
Vivo Capital, LLC	4.76%
Vestal Point Capital LP	4.51%
BlackRock Inc	3.70%
Trails Edge Capital Partners, LP	3.55%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for OnKure Therapeutics, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.